{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IGIV-C&page=2", "query": { "intervention": "IGIV-C", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IGIV-C&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-22T02:33:42.644Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04561115", "title": "A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Immunodeficiency" ], "interventions": [ { "name": "Gamunex-C", "type": "BIOLOGICAL" }, { "name": "IVIG-PEG", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Grifols Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 33, "start_date": "2020-09-02", "completion_date": "2022-03-28", "has_results": true, "last_update_posted_date": "2023-06-05", "last_synced_at": "2026-09-22T02:33:42.644Z", "location_count": 10, "location_summary": "Birmingham, Alabama • North Palm Beach, Florida • South Bend, Indiana + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "North Palm Beach", "state": "Florida" }, { "city": "South Bend", "state": "Indiana" }, { "city": "Chevy Chase", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04561115" }, { "nct_id": "NCT00473824", "title": "Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sequelae of Viral Hepatitis", "Transplantation Infection", "Evidence of Liver Transplantation" ], "interventions": [ { "name": "Hepatitis C Immune Globulin Intravenous (Human) 5%", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ADMA Biologics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 7, "start_date": "2007-05", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2021-07-30", "last_synced_at": "2026-09-22T02:33:42.644Z", "location_count": 3, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00473824" }, { "nct_id": "NCT02473965", "title": "Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myasthenia Gravis" ], "interventions": [ { "name": "IGIV-C", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Grifols Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 60, "start_date": "2015-06", "completion_date": "2019-02", "has_results": true, "last_update_posted_date": "2020-03-30", "last_synced_at": "2026-09-22T02:33:42.644Z", "location_count": 14, "location_summary": "Orange, California • New Haven, Connecticut • Jacksonville, Florida + 11 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02473965" }, { "nct_id": "NCT02042027", "title": "Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Corneal Neovascularization", "Corneal Graft Failure", "Anterior Segment Inflammation" ], "interventions": [ { "name": "Gamunex-C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2014-07", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2016-08-05", "last_synced_at": "2026-09-22T02:33:42.644Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02042027" }, { "nct_id": "NCT06859424", "title": "A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "AML (Acute Myelogenous Leukemia)", "Acute Lymphoid Leukemia (ALL)", "Acute Leukemia (Category)", "MDS (Myelodysplastic Syndrome)", "CML (Chronic Myelogenous Leukemia)", "CLL (Chronic Lymphocytic Leukemia)", "Prolymphocyctic Leukemia", "Chronic Myelomonocytic Leukemia (CMML)", "Myeloproliferative Neoplasm (MPN)", "Lymphoma", "Myelofibrosis" ], "interventions": [ { "name": "Conditioning Regimen A", "type": "DRUG" }, { "name": "Conditioning Regimen B", "type": "DRUG" }, { "name": "Conditioning Regimen C", "type": "DRUG" }, { "name": "Conditioning Regimen D", "type": "DRUG" }, { "name": "Conditioning Regimen E", "type": "DRUG" }, { "name": "Hematopoietic Cell Transplantation", "type": "PROCEDURE" }, { "name": "PTCy (50 mg/kg D3, D4)", "type": "DRUG" }, { "name": "PTCy (25 mg/kg D3, D4)", "type": "DRUG" }, { "name": "Post-transplant Tacrolimus", "type": "DRUG" }, { "name": "Post-transplant Mycophenolate mofetil", "type": "DRUG" }, { "name": "Post-transplant Abatacept", "type": "DRUG" }, { "name": "Post-transplant Ruxolitinib", "type": "DRUG" }, { "name": "Supportive Care: Growth Factors", "type": "DRUG" }, { "name": "Supportive Care: Blood Products", "type": "PROCEDURE" }, { "name": "Supportive Care: Infection Prophylaxis", "type": "OTHER" }, { "name": "Supportive Care: Intravenous immune globulin (IVIG)", "type": "OTHER" }, { "name": "Supportive Care: Seizure prophylaxis", "type": "DRUG" }, { "name": "Supportive Care: Monitoring and management of CRS", "type": "OTHER" }, { "name": "Supportive Care: Prophylaxis against infections", "type": "OTHER" }, { "name": "Supportive Care: Prophylaxis against infections", "type": "DRUG" }, { "name": "Supportive Care: Lipid elevations", "type": "OTHER" }, { "name": "Study treatment compliance", "type": "OTHER" }, { "name": "Prohibited Concomitant Therapy", "type": "OTHER" }, { "name": "Permitted Concomitant Therapy", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Center for International Blood and Marrow Transplant Research", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "66 Years", "sex": "ALL", "summary": "18 Years to 66 Years" }, "enrollment_count": 358, "start_date": "2025-07-25", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-09-22T02:33:42.644Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06859424" }, { "nct_id": "NCT03866577", "title": "Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Immune Thrombocytopenic Purpura (ITP)" ], "interventions": [ { "name": "Biological: M254", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Intravenous immunoglobulin (IVIg)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Momenta Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2018-12-21", "completion_date": "2021-06-09", "has_results": true, "last_update_posted_date": "2025-05-28", "last_synced_at": "2026-09-22T02:33:42.644Z", "location_count": 6, "location_summary": "Los Angeles, California • Whittier, California • Miami Lakes, Florida + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Miami Lakes", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03866577" }, { "nct_id": "NCT06935266", "title": "A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "TAK-881", "type": "BIOLOGICAL" }, { "name": "SC Investigational Needle Sets", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 64, "start_date": "2025-04-22", "completion_date": "2025-09-27", "has_results": true, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-09-22T02:33:42.644Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06935266" }, { "nct_id": "NCT01804829", "title": "Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Infection", "Viruses", "Hepatocellular Carcinoma", "Hepatitis, Viral, Human", "Liver Cirrhosis" ], "interventions": [ { "name": "Civacir® 10%", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Biotest Pharmaceuticals Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 80, "start_date": "2013-06", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2017-03-15", "last_synced_at": "2026-09-22T02:33:42.644Z", "location_count": 23, "location_summary": "Los Angeles, California • San Francisco, California • Miami, Florida + 15 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01804829" }, { "nct_id": "NCT02139657", "title": "An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rabies" ], "interventions": [ { "name": "RIG-C", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Grifols Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 12, "start_date": "2014-03", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2014-07-24", "last_synced_at": "2026-09-22T02:33:42.644Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02139657" }, { "nct_id": "NCT00025038", "title": "Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Juvenile Myelomonocytic Leukemia" ], "interventions": [ { "name": "tipifarnib", "type": "DRUG" }, { "name": "isotretinoin", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "double-unit umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": 100, "start_date": "2001-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-04-11", "last_synced_at": "2026-09-22T02:33:42.644Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00025038" } ] }